SLCO1B1 and tuberculosis: In their review of pharmacokinetics and pharmacogenetics of anti-TB drugs, Motta et al. (2018) suggest that increasing the RFP doses in individuals with SLCO1B1 loss of function alleles is a promising strategy—SLCO1B1 is a transporter of drugs into hepatic cells.